• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Omnicell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/6/25 6:34:17 AM ET
    $OMCL
    Computer Manufacturing
    Technology
    Get the next $OMCL alert in real time by email
    omcl-20250506
    0000926326false00009263262025-05-062025-05-06


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D. C.  20549

    FORM 8-K

    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of Report (Date of earliest event reported):  May 6, 2025

    OMNICELL, INC.
    (Exact name of registrant as specified in its charter)

    Delaware000-3304394-3166458
    (State or other jurisdiction of
    incorporation)
    (Commission File Number)(IRS Employer Identification Number)

    4220 North Freeway
    Fort Worth, TX 76137
    (Address of principal executive offices, including zip code)

    (877) 415-9990
    (Registrant’s telephone number, including area code)


    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading SymbolName of each exchange on which registered
    Common Stock, $0.001 par valueOMCLNASDAQ Global Select Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 2.02 Results of Operations and Financial Condition.
    On May 6, 2025, Omnicell, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025 and updating its guidance for the full year 2025. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
    The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
    Item 9.01 Financial Statements and Exhibits.
    (d) Exhibits.
    Exhibit NumberExhibit Description
    99.1
    Press release entitled “Omnicell Announces First Quarter 2025 Results” dated May 6, 2025
    104Cover Page Interactive Data File (embedded within the inline XBRL document)




    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

    OMNICELL, INC.
    Date: May 6, 2025
    /s/ Nchacha E. Etta
    Nchacha E. Etta
    Executive Vice President and Chief Financial Officer




    Get the next $OMCL alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $OMCL

    DatePrice TargetRatingAnalyst
    5/14/2025$35.00Equal Weight → Overweight
    Wells Fargo
    10/31/2024$44.00 → $57.00Buy → Neutral
    BofA Securities
    8/2/2024$26.00 → $39.00Underweight → Equal Weight
    Barclays
    1/3/2024$33.00Underweight
    Barclays
    11/3/2023$39.00 → $28.00Underweight → Equal Weight
    Wells Fargo
    11/3/2023Buy → Neutral
    BTIG Research
    11/3/2023$70.00 → $39.00Neutral → Overweight
    Piper Sandler
    10/11/2023Overweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $OMCL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHAIRMAN, PRESIDENT AND CEO Lipps Randall A bought $349,874 worth of shares (10,561 units at $33.13) and was granted 79,494 shares, increasing direct ownership by 28% to 413,104 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      3/18/25 4:13:27 PM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    SEC Filings

    See more
    • SEC Form S-8 filed by Omnicell Inc.

      S-8 - OMNICELL, INC. (0000926326) (Filer)

      6/18/25 4:04:58 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - OMNICELL, INC. (0000926326) (Filer)

      6/5/25 5:13:20 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - OMNICELL, INC. (0000926326) (Filer)

      5/23/25 4:34:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHAIRMAN, PRESIDENT AND CEO Lipps Randall A covered exercise/tax liability with 1,146 shares, decreasing direct ownership by 0.28% to 403,523 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      6/17/25 5:27:57 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • EVP&CHIEF LEGAL/ADMIN OFFICER Manley Corey J covered exercise/tax liability with 332 shares, decreasing direct ownership by 0.28% to 117,126 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      6/17/25 5:27:11 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Director Parrish Mark W was granted 6,828 shares, increasing direct ownership by 12% to 65,255 units (SEC Form 4)

      4 - OMNICELL, INC. (0000926326) (Issuer)

      6/3/25 4:12:37 PM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Omnicell to Release Second Quarter 2025 Financial Results on July 31, 2025

      Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the second quarter 2025, before market open on Thursday, July 31, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 3131192. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. A

      7/14/25 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Expects Improved Profitability, Updates Second Quarter and Full Year 2025 Profit Outlook and Announces a New Stock Repurchase Program

      Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced updates to its second quarter and full year 2025 outlook for Non-GAAP EBITDA and Non-GAAP earnings per share, and the authorization of a new $75 million stock repurchase program. "The Administration's recent announcement of a reduction in tariff rates on imports from China has compelled us to update our second quarter and full-year 2025 outlook to reflect the expected diminished impact on our supply chain and anticipated improved profitability," stated Randall Lipps, chairman, president, chief executive officer,

      5/22/25 8:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Announces New Products for Perioperative and Clinic Settings

      RFID-Enabled Dispensing and Intelligent Inventory Management Software Aim to Unlock Greater Inventory Accuracy and Streamline Medication Management in Operating Rooms and Outpatient Clinics Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced new products designed to streamline workflows and enhance inventory visibility and management in perioperative and clinic settings. These products, which leverage RFID tracking and intelligent software workflows, expand Omnicell's connected platform that is intended to automate medication management processes and deliver intelligent insights to drive clinical

      5/14/25 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Omnicell upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Omnicell from Equal Weight to Overweight and set a new price target of $35.00

      5/14/25 8:50:33 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell downgraded by BofA Securities with a new price target

      BofA Securities downgraded Omnicell from Buy to Neutral and set a new price target of $57.00 from $44.00 previously

      10/31/24 7:49:39 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell upgraded by Barclays with a new price target

      Barclays upgraded Omnicell from Underweight to Equal Weight and set a new price target of $39.00 from $26.00 previously

      8/2/24 7:36:45 AM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Leadership Updates

    Live Leadership Updates

    See more
    • Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer

      The Company taps business and operations executive with expertise that spans healthcare and med tech to help scale pharmacy automation and drive multi-year innovation and excellence Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of the Company, effective October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240925324631/en/Nnamdi Njoku has been appointed Executive Vice President and Chief Operating Officer of Omnicell, effective October 7, 2024

      9/25/24 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Clover Health Appoints Healthcare Technology Veteran Peter Kuipers as Chief Financial Officer

      FRANKLIN, Tenn., April 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company, today announced the appointment of Peter Kuipers as Chief Financial Officer ("CFO"), effective as of the day after the filing of the Company's Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024. With a wealth of experience and a proven track record in financial management, Mr. Kuipers will drive strategic financial initiatives around profitability, growth and potential new revenue streams. Recognized with the 2018 San Francisco Bay Area Public Company CFO of the Year Award for small to me

      4/22/24 4:05:00 PM ET
      $CLOV
      $OMCL
      Medical Specialities
      Health Care
      Computer Manufacturing
      Technology
    • Omnicell Elects Eileen Voynick to Board of Directors

      Sales and Operational Veteran Brings Additional Global Business Experience and Healthcare Technology Expertise to Board Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that the Board of Directors elected Eileen Voynick to the Board, effective January 5, 2024. Ms. Voynick fills the vacancy resulting from Sara J. White, a Class I director who stepped down from the Company's Board of Directors, effective January 5, 2024. In addition, the Company announced that Vance Moore will not stand for reelection to the Company's Board at Omnicell's 2024 annual meeting of stockholders (the "2024 annual meeting") and e

      1/11/24 4:00:00 PM ET
      $MDRX
      $OMCL
      $CDK
      EDP Services
      Technology
      Computer Manufacturing
      Retail: Computer Software & Peripheral Equipment

    $OMCL
    Financials

    Live finance-specific insights

    See more
    • Omnicell to Release Second Quarter 2025 Financial Results on July 31, 2025

      Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the second quarter 2025, before market open on Thursday, July 31, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 3131192. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. A

      7/14/25 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell Announces First Quarter 2025 Results

      Omnicell delivers solid first quarter financial results Results exceed previously issued first quarter 2025 guidance for total revenues and non-GAAP EPS Updates full year 2025 non-GAAP EBITDA and non-GAAP EPS guidance Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its first quarter ended March 31, 2025. "We delivered strong financial results for the first quarter of 2025, exceeding our previously provided guidance ranges for both revenue and earnings, which we believe reflects customers embracing the industry-defined vision of the Autonomous P

      5/6/25 6:30:00 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • Omnicell to Release First Quarter 2025 Financial Results on May 6, 2025

      Omnicell, Inc. (NASDAQ:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the first quarter 2025, before market open on Tuesday, May 6, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day. All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the U.S. or (646) 307-1963 in international locations. The Conference ID is 7437144. A link to the live and archived webcast will also be available on the Investor Relations section of Omnicell's website at https://ir.omnicell.com/events-and-presentations/. About O

      4/14/25 4:01:00 PM ET
      $OMCL
      Computer Manufacturing
      Technology

    $OMCL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

      SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

      12/11/23 9:36:42 AM ET
      $OMCL
      Computer Manufacturing
      Technology
    • SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

      SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

      9/11/23 1:33:44 PM ET
      $OMCL
      Computer Manufacturing
      Technology
    • SEC Form SC 13G/A filed by Omnicell Inc. (Amendment)

      SC 13G/A - OMNICELL, INC. (0000926326) (Subject)

      2/9/23 11:27:45 AM ET
      $OMCL
      Computer Manufacturing
      Technology